ACS Chemical Biology

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference

Retrieved on: 
Thursday, May 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, ASMS, CSF, Data analysis, Software, American Society for Mass Spectrometry, Fish acute toxicity syndrome, Yale School of Medicine, Machine learning, Proteome, University of Copenhagen, Proteomics, Patient, Environment, Mass spectrometry, SLE, Solution, Buck, Health, GLP, Johns Hopkins University, HRM, Society, Lupus, Trial of the century, AD, Research, Algorithm, Buck Institute for Research on Aging, Plasma, Conference, DIA, CDK, University, Biomarker, Drug development, ACS Chemical Biology, Protein, Proteoform, Drug discovery, Acquisition, Artificial intelligence, Data-independent acquisition, GCP, AstraZeneca, Body fluid, Medical imaging, Pharmaceutical industry, Fine chemical, Online shopping

Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration.

Key Points: 
  • Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration.
  • Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics, said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
  • "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.
  • At this years ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars.

Exo Therapeutics Appoints Laura Kiessling to Scientific Advisory Board

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, CEO, Howard Hughes Medical Institute, MIT, Secondary research, Massachusetts Institute of Technology, Salk Institute for Biological Studies, Faculty, Laurens Anderson, Research, Broad Institute, Exo, Chemogenomics, Yale University, Science, Creativity, The arts, National academy, Learning, Jude the Apostle, Novartis, Doctor of Philosophy, Therapy, American, Steenbok, Inflammation, Hospital, Genomics, Harvard University, American Philosophical Society, National Academy of Sciences, Dana, American Academy, Scripps Research, SAB, Multimedia, Dana–Farber Cancer Institute, University, Carbohydrate, ACS Chemical Biology, Pharmaceutical industry, Biochemistry, Technology, Chemistry, MD

Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that bind to exosites, today announced the appointment of Laura Kiessling, PhD, to the companys Scientific Advisory Board (SAB).

Key Points: 
  • Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that bind to exosites, today announced the appointment of Laura Kiessling, PhD, to the companys Scientific Advisory Board (SAB).
  • Dr. Kiesslings creativity and broad scientific expertise will be crucial as we continue to build our platform and drive new programs to the clinic.
  • Exos experienced, collaborative and dedicated team is passionate about pioneering exosite science to unlock breakthrough therapeutics.
  • Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets.

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Society, Cancer, Therapy, Clinical trial, Security (finance), Food, Insurance, Treatment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Public expenditure, Multiple myeloma, Blood, Risk, PK, Safety, Biogen, Synovial sarcoma, IND, Research, Mantle cell lymphoma, Â, Conference, RET, U.S. Securities and Exchange Commission, GLOBE, Program, CCCC, Patient, ACS Chemical Neuroscience, Private Securities Litigation Reform Act, G&A, R, Peripheral T-cell lymphoma, Controlled Impact Demonstration, Finance, Evercore, Jaden Philogene-Bidace, BRAF, Sarah Cannon Research Institute, Computation, BRD9, Drug resistance, ASH, Research and development, Administration, Workforce, Annual report, ACS Chemical Biology, Pharmaceutical industry, Fine chemical, Animal, Vaccine, Lithium

WATERTOWN, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today reported business highlights and financial results for the third quarter of 2021.

Key Points: 
  • Revenue: Total revenue for the third quarter of 2021 was $8.5 million, compared to $8.4 million for the third quarter of 2020.
  • Research and Development (R&D) Expense: R&D expense for the third quarter of 2021 was $24.3 million, compared to $23.9 million for the third quarter of 2020.
  • General and Administrative (G&A) Expense: G&A expense for the third quarter of 2021 was $8.5 million, compared to $2.9 million for the third quarter of 2020.
  • Net loss per share for the third quarter of 2021 was $0.51, compared to $17.55 for the third quarter of 2020.